It's crunch time for biotech projects started on a bet that the industry would shake off its multiyear malaise.

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

News of the layoffs come just one day after the company reported a 5% year over year revenue increase — boosting revenue to ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...

At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.